NorthWest Biotherapeutics Inc (NWBO)

[NOTBOB17]

The WPRI segment on glioblastoma further indicated that our investment in NWBO is almost completely de-risked. However it will do nothing for
publicity and/or share price increases. Nothing of consequence will happen until the MAA application is submitted and announced. Even then, submission might not
induce a significant share price increase. No true long learned anything new from this segment and retail investors will not pause the tape on the JAMA page and read the fine print to identify NWBO as the company behind DCVax-L. Approval is the holy grail. Until then, or some other blockbuster news (read lawsuit)....who knows what happens to the price. I remain long and bullish,, but frustrated at the length of time for this to mature.